FERROUS FUMARATE, FOLIC ACID

Brand names: Prenatryl, Prometa, Prenatrix, Folitin-Z, Vitranol Fe, Pretrate, Ventrixyl Fe, Foliflex, Zintrexyl-C, Ribotin-E, Venexa FE, Vitrexate FE, Vitrexyl plus Iron

Boxed warning

WARNING Accidental overdose of iron-containing products is a leading cause of fatal poisoning in children under 6. Keep this product out of reach of children. In case of accidental overdose, call a doctor or poison control center immediately. Administration of folic acid alone is improper therapy for pernicious anemia and other megaloblastic anemias in which vitamin B 12 is deficient. Precautions Folic acid in doses above 0.1 mg daily may obscure pernicious anemia, in that hematologic remission can occur while neurological manifestations remain progressive. There is a potential danger in administering folic acid to patients with undiagnosed anemia, since folic acid may obscure the diagnosis of pernicious anemia by alleviating the hematologic manifestations of the disease while allowing the neurologic complications to progress. This may result in severe nervous system damage before the correct diagnosis is made. Adequate doses of vitamin B 12 may prevent, halt, or improve the neurologic changes caused by pernicious anemia. The patient’s medical conditions and consumption of other drugs, herbs, and/or supplements should be considered. For use on the order of a healthcare practitioner. Call your doctor about side effects. To report side effects, call PureTek Corporation at 1-877-921-7873 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Warnings

WARNING: Accidental overdose of iron-containing products is a leading cause of fatal poisoning in children under 6. Keep this product out of reach of children. In case of accidental overdose, call a doctor or poison control center immediately. Administration of folic acid alone is improper therapy for pernicious anemia and other megaloblastic anemias in which vitamin B12 is deficient. Precaution Section Folic acid in doses above 0.1 mg daily may obscure pernicious anemia, in that hematologic remission can occur while neurological manifestations remain progressive. There is a potential danger in administering folic acid to patients with undiagnosed anemia, since folic acid may obscure the diagnosis of pernicious anemia by alleviating the hematologic manifestations of the disease while allowing the neurologic complications to progress. This may result in severe nervous system damage before the correct diagnosis is made. Adequate doses of vitamin B12 may prevent, halt, or improve the neurologic changes caused by pernicious anemia. The patient’s medical conditions and consumption of other drugs, herbs, and/or supplements should be considered. For use on the order of a healthcare practitioner. Call your doctor about side effects. To report side effects, call PureTek Corporation at 1-877-921-7873 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. Drug Interactions: Folitin-Z TM is not recommended for and should not be given to patients receiving levodopa because the action of levodopa is antagonized by pyridoxine. There is a possibility of increased bleeding due to pyridoxine interaction with anticoagulants (e.g., Aspirin, Heparin, or Clopidogrel). Adverse Reactions: Folic Acid: Allergic sensitizations have been reported following both oral and parenteral administration of folic acid. Ferrous Fumarate: Gastrointestinal disturbances (anorexia, nausea, diarrhea, constipation) occur occasionally, but are usually mild and may subside with continuation of therapy. Although the absorption of iron is best when taken between meals, giving Folitin-Z TM after meals may control occasional gastrointestinal disturbances. Folitin-Z TM is best absorbed when taken at bedtime. Adverse reactions have been reported with specific vitamins and minerals but generally at levels substantially higher than those contained herein. However, allergic and idiosyncratic reactions are possible at lower levels. Iron, even at the usually recommended levels, has been associated with gastrointestinal intolerance in some patients.

Contraindications

CONTRAINDICATIONS: This product is contraindicated in patients with known hypersensitivity to any of its ingredients; also, all iron compounds are contraindicated in patients with hemosiderosis, hemochromatosis, or hemolytic anemias. Pernicious anemia is a contraindication, as folic acid may obscure its signs and symptoms.

Overdose

OVERDOSE: Iron: Signs and Symptoms: Iron is toxic. Acute overdosage of iron may cause nausea and vomiting and, in severe cases, cardiovascular collapse and death. Other symptoms include pallor and cyanosis, melena, shock, drowsiness, and coma. The estimated overdose of orally ingested iron is 300 mg/kg body weight. When overdoses are ingested by children, severe reactions, including fatalities, have resulted. Vitrexate FE should be stored beyond the reach of children to prevent accidental iron poisoning. Keep this and all other drugs out of reach of children. Treatment: For specific therapy, exchange transfusion and chelating agents should be used. For general management, perform gastric lavage with sodium bicarbonate solution or milk. Administer intravenous fluids and electrolytes and use oxygen.

Drug interactions

Drug Interactions: Vitrexate FE is not recommended for and should not be given to patients receiving levodopa because the action of levodopa is antagonized by pyridoxine. There is a possibility of increased bleeding due to pyridoxine interaction with anticoagulants (e.g., Aspirin, Heparin or Clopidogrel).

Uses

Indications Indicated to provide vitamins and minerals to women throughout pregnancy and during the postnatal period for both lactating and non-lactating mothers, and throughout the childbearing years. May be beneficial in improving the nutritional status of women prior to conception.

Dosage forms & strengths

TABLET
MAGNESIUM OXIDE 200 mg/1 MANGANESE SULFATE 2.6 mg/1 VITAMIN A ACETATE 1500 ug/1 ASCORBIC ACID 120 mg/1 CHOLECALCIFEROL 20 ug/1 .ALPHA.-TOCOPHEROL ACETATE, DL- 30 mg/1 THIAMINE MONONITRATE 3 mg/1 RIBOFLAVIN 3.4 mg/1 NIACINAMIDE 20 mg/1 PYRIDOXINE HYDROCHLORIDE 50 mg/1 FOLIC ACID 1000 ug/1 CYANOCOBALAMIN 10 ug/1 CALCIUM CARBONATE 200 mg/1 FERROUS FUMARATE 27 mg/1 ZINC OXIDE 25 mg/1 MOLYBDENUM 50 ug/1 CHOLINE BITARTRATE 55 mg/1 SELENIUM 70 ug/1 CHROMIUM NICOTINATE 45 ug/1 POTASSIUM IODIDE 150 ug/1 ASCORBIC ACID 250 mg/1 CHOLECALCIFEROL 13.75 ug/1 .ALPHA.-TOCOPHEROL ACETATE, DL- 45 mg/1 THIAMINE MONONITRATE 3.25 mg/1 RIBOFLAVIN 3.35 mg/1 NIACINAMIDE 22.5 mg/1 PYRIDOXINE HYDROCHLORIDE 6 mg/1 FOLIC ACID 500 ug/1 CYANOCOBALAMIN 13 ug/1 BIOTIN 100 ug/1 PANTOTHENIC ACID 15 mg/1 CALCIUM CARBONATE 75 mg/1 FERROUS FUMARATE 9 mg/1 POTASSIUM IODIDE 25 ug/1 MAGNESIUM OXIDE 37.5 mg/1 ZINC OXIDE 15 mg/1 SELENIUM 30 ug/1 CUPROUS OXIDE 1 mg/1 MANGANESE SULFATE .75 mg/1 CHROMIUM NICOTINATE 37.5 ug/1 MOLYBDENUM 25 ug/1 POTASSIUM CHLORIDE 24.5 mg/1 BORON 25 ug/1 CHROMIUM NICOTINATE 35 ug/1 PYRIDOXINE HYDROCHLORIDE 20 mg/1 CYANOCOBALAMIN 8 ug/1 MANGANESE SULFATE 2.3 mg/1 MOLYBDENUM 45 ug/1 SELENIUM 55 ug/1

DOSAGE AND ADMINISTRATION: Adults (persons over 12 years of age) One (1) VitrexylTM + Iron caplet daily, between meals or as directed by a physician. Do not administer to children under the age of 12.

All identified pills

Side effects

Adverse Reactions: Folic Acid: Allergic sensitizations have been reported following both oral and parenteral administration of folic acid. Ferrous Fumarate: Gastrointestinal disturbances (anorexia, nausea, diarrhea, constipation) occur occasionally, but are usually mild and may subside with continuation of therapy. Although the absorption of iron is best when taken between meals, giving after meals may control occasional gastrointestinal disturbances. It is best absorbed when taken at bedtime. Adverse reactions have been reported with specific vitamins and minerals but generally at levels substantially higher than those contained herein. However, allergic and idiosyncratic reactions are possible at lower levels. Iron, even at the usual recommended levels, has been associated with gastrointestinal intolerance in some patients.

Official source

DailyMed